A High Throughput Biochemical Fluorometric Method for Measuring Lipid Peroxidation in HDL

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Kelesidis, Theodoros ^a   Roberts, Christian K ^a   Huynh, Diana ^a   Martínez Maza, Otoniel ^b   Currier, Judith S ^a   Reddy, Srinivasa T ^a,b   Yang, Otto O ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HIGH DENSITY LIPOPROTEIN; PRAVASTATIN; PROTEINASE INHIBITOR; AMPLEX RED REAGENT; OXAZINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHROPOMETRIC PARAMETERS; ANTIBODY AFFINITY; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BIOCHEMICAL ANALYSIS; CARDIOVASCULAR DISEASE; CELL ASSAY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; FLUOROMETRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; LIPID PEROXIDATION; MALE; METABOLIC PARAMETERS; MOUSE; NONHUMAN; PROTEIN FUNCTION; REPRODUCIBILITY; ADOLESCENT; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; CORONARY ARTERY DISEASE; HIGH THROUGHPUT SCREENING; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; CAROTID INTIMA-MEDIA THICKNESS; CORONARY ARTERY DISEASE; FEMALE; FLUOROMETRY; HIGH-THROUGHPUT SCREENING ASSAYS; HIV INFECTIONS; HIV-1; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, HDL; MALE; MICE, INBRED C57BL; MIDDLE AGED; OXAZINES; YOUNG ADULT;

EID: 84932191182     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111716     Document Type: Article

References (78)

1. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM (2011) HDL and cardiovascular disease: Atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 8: 222-232. nrcardio.2010.222 [pii]; 10.1038/nrcardio.2010.222 [doi].
2. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM (2009) The role of dysfunctional HDL in atherosclerosis. J Lipid Res 50 Suppl: S145-S149. R800036-JLR200 [pii]; 10.1194/jlr.R800036-JLR200 [doi].
3. Khera AV, Cuchel M, Llera-Moya M, Rodrigues A, Burke MF, et al. (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364: 127-135. 10.1056/NEJMoa1001689 [doi].
4. Patel PJ, Khera AV, Jafri K, Wilensky RL, Rader DJ (2011) The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol 58: 2068-2075. S0735-1097(11)03137-8 [pii]; 10.1016/j.jacc.2011.08.030 [doi].
5. Patel S, Drew BG, Nakhla S, Duffy SJ, Murphy AJ, et al. (2009) Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol 53: 962-971. S0735-1097(08)04128-4 [pii]; 10.1016/j.jacc.2008.12.008 [doi].
6. Undurti A, Huang Y, Lupica JA, Smith JD, DiDonato JA, et al.(2009) Modification of high density lipoprotein by myeloperoxidase generates a proinflammatory particle. J Biol Chem 284: 30825-30835. M109.047605 [pii]; 10.1074/jbc.M109.047605 [doi].
7. Van Lenten BJ, Wagner AC, Navab M, Anantharamaiah GM, Hama S, et al. (2007) Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res 48: 2344-2353. M700138-JLR200 [pii]; 10.1194/jlr.M700138-JLR200 [doi].
8. Watson CE, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, et al. (2011) Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res 52: 361-373. jlr.M011098 [pii]; 10.1194/jlr.M011098 [doi].
9. Movva R, Rader DJ (2008) Laboratory assessment of HDL heterogeneity and function. Clin Chem 54: 788-800. clinchem.2007.101923 [pii]; 10.1373/clinchem.2007.101923 [doi].
10. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, et al. (2004) The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. J Lipid Res 45: 993-1007. 10.1194/jlr.R400001-JLR200 [doi]; R400001-JLR200 [pii].
11. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, et al. (2006) Mechanisms of disease: Proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2: 504-511. ncpendmet0245 [pii]; 10.1038/ncpendmet0245 [doi].
12. Kelesidis T, Currier JS, Huynh D, Meriwether D, Charles-Schoeman C, et al. (2011) A biochemical fluorometric method for assessing the oxidative properties of HDL. J Lipid Res 52: 2341-2351. jlr.D018937 [pii]; 10.1194/jlr.D018937 [doi].
13. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, et al. (2001) A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 42: 1308-1317.
14. Watanabe J, Grijalva V, Hama S, Barbour K, Berger FG, et al. (2009) Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J Biol Chem 284: 18292-18301. M109.017202 [pii]; 10.1074/jbc.M109.017202 [doi].
15. Morgantini C, Natali A, Boldrini B, Imaizumi S, Navab M, et al. (2011) Antiinflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes 60: 2617-2623. db11-0378 [pii]; 10.2337/db11-0378 [doi].
16. Imaizumi S, Grijalva V, Navab M, Van Lenten BJ, Wagner AC, et al. (2010) L-4F Differentially Alters Plasma Levels of Oxidized Fatty Acids Resulting in More Anti-inflammatory HDL in Mice. Drug Metab Lett 4: 139-148. BSP/DML/EPub/00042 [pii].
17. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, et al. (2009) Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 60: 2870-2879. 10.1002/art.24802 [doi].
18. Watanabe J, Chou KJ, Liao JC, Miao Y, Meng HH, et al. (2007) Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis. J Biol Chem 282: 23698-23707. M702163200 [pii]; 10.1074/jbc.M702163200 [doi].
19. Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, et al. (2012) Proteomic profiling following immunoaffinity capture of HDL: Association of acute phase proteins and complement factors with pro-inflammatory HDL in rheumatoid arthritis. Arthritis Rheum 64: 1828-1837. 10.1002/art.34363 [doi].
20. Ji X, Xu H, Zhang H, Hillery CA, Gao HQ, et al. (2014) Anion exchange HPLC isolation of high-density lipoprotein (HDL) and on-line estimation of proinflammatory HDL. PLoS One 9: E91089. 10.1371/journal.pone.0091089 [doi]; PONE-D-14-01051 [pii].
21. Weihrauch D, Xu H, Shi Y, Wang J, Brien J, et al. (2007) Effects of D-4F on vasodilation, oxidative stress, angiostatin, myocardial inflammation, and angiogenic potential in tight-skin mice. Am J Physiol Heart Circ Physiol 293: H1432-H1441. 00038.2007 [pii]; 10.1152/ajpheart.00038.2007 [doi].
22. Kelesidis T, Reddy ST, Huynh D, Meriwether D, Fogelman AM, et al. (2012) Effects of lipid-probe interactions in biochemical fluorometric methods that assess HDL redox activity. Lipids Health Dis 11: 87. 1476-511X-11-87 [pii]; 10.1186/1476-511X-11-87 [doi].
23. Havel RJ, Eder HA, Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353. 10.1172/JCI103182 [doi].
24. Hedrick CC, Castellani LW, Warden CH, Puppione DL, Lusis AJ (1993) Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol Chem 268: 20676-20682.
25. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, et al. (1995) Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96: 2882-2891. 10.1172/JCI118359 [doi].
26. Widhalm K, Pakosta R (1991) Precipitation with polyethylene glycol and density-gradient ultracentrifugation compared for determining high-density lipoprotein subclasses HDL2 and HDL3. Clin Chem 37: 238-240.
27. (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486-2497. jsc10094 [pii].
28. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS (2012) Biomarkers of microbial translocation and macrophage activation: Association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 206: 1558-1567. jis545 [pii]; 10.1093/infdis/jis545 [doi].
29. Anonymous (2011) Available: Http://www.redcrossblood.org/donating-blood/eligibility-requirements.
30. Boulton F (2008) Evidence-based criteria for the care and selection of blood donors, with some comments on the relationship to blood supply, and emphasis on the management of donation-induced iron depletion. Transfus Med 18: 13-27. TME818 [pii]; 10.1111/j.1365-3148.2007.00818.x [doi].
31. Price TH (2008) Standards for blood banks and transfusion services. 25th ed: 20.
32. Navab M, Anantharamaiah GM, Hama S, Hough G, Reddy ST, et al. (2005) D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 25: 1426-1432. 01.ATV.0000167412.98221.1a [pii]; 10.1161/01.ATV.0000167412.98221.1a [doi].
33. Roberts CK, Croymans DM, Aziz N, Butch AW, Lee CC (2013) Resistance training increases SHBG in overweight/obese, young men. Metabolism 62: 725-733. S0026-0495(12)00457-X [pii]; 10.1016/j.metabol.2012.12.004 [doi].
34. Amundson DM, Zhou M (1999) Fluorometric method for the enzymatic determination of cholesterol. J Biochem Biophys Methods 38: 43-52. S0165-022X(98)00036-0 [pii].
35. Mishin V, Gray JP, Heck DE, Laskin DL, Laskin JD (2010) Application of the Amplex red/horseradish peroxidase assay to measure hydrogen peroxide generation by recombinant microsomal enzymes. Free Radic Biol Med 48: 1485-1491. S0891-5849(10)00132-2 [pii]; 10.1016/j.freeradbiomed.2010.02. 030 [doi].
36. Bhattacharya A, Muller FL, Liu Y, Sabia M, Liang H, et al. (2009) Denervation induces cytosolic phospholipase A2-mediated fatty acid hydroperoxide generation by muscle mitochondria. J Biol Chem 284: 46-55. M806311200 [pii]; 10.1074/jbc.M806311200 [doi].
37. Lombardi A, Busiello RA, Napolitano L, Cioffi F, Moreno M, et al. (2010) UCP3 translocates lipid hydroperoxide and mediates lipid hydroperoxidedependent mitochondrial uncoupling. J Biol Chem 285: 16599-16605. M110.102699 [pii]; 10.1074/jbc.M110.102699 [doi].
38. Gutheil WG, Stefanova ME, Nicholas RA (2000) Fluorescent coupled enzyme assays for D-alanine: Application to penicillin-binding protein and vancomycin activity assays. Anal Biochem 287: 196-202. 10.1006/abio.2000.4835 [doi]; S0003-2697(00)94835-8 [pii].
39. Peus D, Vasa RA, Beyerle A, Meves A, Krautmacher C, et al. (1999) UVB activates ERK1/2 and p38 signaling pathways via reactive oxygen species in cultured keratinocytes. J Invest Dermatol 112: 751-756. 10.1046/j.1523-1747.1999.00584.x [doi].
40. Richer SC, Ford WC (2001) A critical investigation of NADPH oxidase activity in human spermatozoa. Mol Hum Reprod 7: 237-244.
41. Kalyanaraman B, Darley-Usmar V, Davies KJ, Dennery PA, Forman HJ, et al. (2012) Measuring reactive oxygen and nitrogen species with fluorescent probes: Challenges and limitations. Free Radic Biol Med 52: 1-6. S0891-5849(11)00605-8 [pii]; 10.1016/j.freeradbiomed.2011.09.030 [doi].
42. Kelesidis T, Yang OO, Kendall MA, Hodis HN, Currier JS (2013) Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and-uninfected adults. Lipids Health Dis 12: 23. 1476-511X-12-23 [pii]; 10.1186/1476-511X-12-23 [doi].
43. Wardman P (2007) Fluorescent and luminescent probes for measurement of oxidative and nitrosative species in cells and tissues: Progress, pitfalls, and prospects. Free Radic Biol Med 43: 995-1022. S0891-5849(07)00459-5 [pii]; 10.1016/j.freeradbiomed.2007.06.026 [doi].
44. Roche M, Rondeau P, Singh NR, Tarnus E, Bourdon E (2008) The antioxidant properties of serum albumin. FEBS Lett 582: 1783-1787. S0014-5793(08)00396-7 [pii]; 10.1016/j.febslet.2008.04.057 [doi].
45. Jayaraman S, Gantz DL, Gursky O (2007) Effects of oxidation on the structure and stability of human low-density lipoprotein. Biochemistry 46: 5790-5797. 10.1021/bi700225a [doi].
46. Roberts CK, Ng C, Hama S, Eliseo AJ, Barnard RJ (2006) Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol 101: 1727-1732. 00345.2006 [pii]; 10.1152/japplphysiol.00345.2006 [doi].
47. Volkmann ER, Grossman JM, Sahakian LJ, Skaggs BJ, FitzGerald J, et al. (2010) Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62: 258-265. 10.1002/acr.20076 [doi].
48. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, et al. (1996) The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 16: 831-842.
49. Mackness MI, Durrington PN, Mackness B (2004) The role of paraoxonase 1 activity in cardiovascular disease: Potential for therapeutic intervention. Am J Cardiovasc Drugs 4: 211-217. 442 [pii].
50. Van Lenten BJ, Hama SY, De Beer FC, Stafforini DM, McIntyre TM, et al. (1995) Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96: 2758-2767. 10.1172/JCI118345 [doi].
51. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, et al. (2001) HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21: 481-488.
52. Hayek T, Oiknine J, Brook JG, Aviram M (1994) Role of HDL apolipoprotein E in cellular cholesterol efflux: Studies in apo E knockout transgenic mice. Biochem Biophys Res Commun 205: 1072-1078. S0006-291X(84)72775-6 [pii]; 10.1006/bbrc.1994.2775 [doi].
53. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, et al. (2005) The double jeopardy of HDL. Ann Med 37: 173-178. V181K7175J7J 4576 [pii]; 10.1080/07853890510007322 [doi].
54. Khera AV, Patel PJ, Reilly MP, Rader DJ (2013) The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol 62: 1909-1910. S0735-1097(13)02868-4 [pii]; 10.1016/j.jacc.2013.07.025 [doi].
55. Patel PJ, Khera AV, Wilensky RL, Rader DJ (2013) Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. Eur J Heart Fail 15: 1215-1219. hft084 [pii]; 10.1093/eurjhf/hft084 [doi].
56. Morgantini C, Meriwether D, Baldi S, Venturi E, Pinnola S, et al. (2014) HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease. Nutr Metab Cardiovasc Dis. S0939-4753(14)00004-0 [pii]; 10.1016/j.numecd.2013.12.011 [doi].
57. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, et al. (2003) Labile plasma iron in iron overload: Redox activity and susceptibility to chelation. Blood 102: 2670-2677. 10.1182/blood-2003-03-0807 [doi]; 2003-03-0807 [pii].
58. Roberts CK, Katiraie M, Croymans DM, Yang OO, Kelesidis T (2013) Untrained young men have dysfunctional HDL compared with strength-trained men irrespective of body weight status. J Appl Physiol(1985) 115: 1043-1049. japplphysiol.00359.2013 [pii]; 10.1152/japplphysiol.00359.2013 [doi].
59. Zanni MV, Kelesidis T, Fitzgerald ML, Lo J, Abbara S, et al. (2014) HDL redox activity is increased in HIV-infected men in association with macrophage activation and noncalcified coronary atherosclerotic plaque. Antivir Ther. 10.3851/IMP2756 [doi].
60. Holzer M, Trieb M, Konya V, Wadsack C, Heinemann A, et al. (2013) Aging affects high-density lipoprotein composition and function. Biochim Biophys Acta 1831: 1442-1448. S1388-1981(13)00127-3 [pii]; 10.1016/j.bbalip.2013.06.004 [doi].
61. Castellani LW, Navab M, Van Lenten BJ, Hedrick CC, Hama SY, et al. (1997) Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest 100: 464-474. 10.1172/JCI119554 [doi].
62. Sattler W, Christison J, Stocker R (1995) Cholesterylester hydroperoxide reducing activity associated with isolated high-and low-density lipoproteins. Free Radic Biol Med 18: 421-429. 089158499400170O [pii].
63. Garner B, Witting PK, Waldeck AR, Christison JK, Raftery M, et al. (1998) Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. J Biol Chem 273: 6080-6087.
64. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker R (1998) Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 273: 6088-6095.
65. Bowry VW, Stanley KK, Stocker R (1992) High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A 89: 10316-10320.
66. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, et al. (2004) Antiinflammatory properties of HDL. Circ Res 95: 764-772. 95/8/764 [pii]; 10.1161/01.RES.0000146094.59640.13 [doi].
67. Daugherty A, Dunn JL, Rateri DL, Heinecke JW (1994) Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 94: 437-444. 10.1172/JCI117342 [doi].
68. Anantharamaiah GM, Hughes TA, Iqbal M, Gawish A, Neame PJ, et al. (1988) Effect of oxidation on the properties of apolipoproteins A-I and A-II. J Lipid Res 29: 309-318.
69. Wang XS, Shao B, Oda MN, Heinecke JW, Mahler S, et al. (2009) A sensitive and specific ELISA detects methionine sulfoxide-containing apolipoprotein A-I in HDL. J Lipid Res 50: 586-594. D800042-JLR200 [pii]; 10.1194/jlr.D800042-JLR200 [doi].
70. Kagramanov V, Lyman A (2001) Noninvasive ventilation and nosocomial infection. JAMA 285: 881. jlt0221-3 [pii].
71. DeMaio L, Rouhanizadeh M, Reddy S, Sevanian A, Hwang J, et al. (2006) Oxidized phospholipids mediate occludin expression and phosphorylation in vascular endothelial cells. Am J Physiol Heart Circ Physiol 290: H674-H683. 00554.2005 [pii]; 10.1152/ajpheart.00554.2005 [doi].
72. Ischiropoulos H, Gow A, Thom SR, Kooy NW, Royall JA, et al. (1999) Detection of reactive nitrogen species using 2,7-dichlorodihydrofluorescein and dihydrorhodamine 123. Methods Enzymol 301: 367-373.
73. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr. (2008) Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA 299: 2287-2293. 299/19/2287 [pii]; 10.1001/jama.299.19.2287 [doi].
74. Tan Y, Liu TR, Hu SW, Tian D, Li C, et al. (2014) Acute coronary syndrome remodels the protein cargo and functions of high-density lipoprotein subfractions. PLoS One 9: E94264. 10.1371/journal.pone.0094264 [doi]; PONE-D-13-49369 [pii].
75. Borja MS, Zhao L, Hammerson B, Tang C, Yang R, et al. (2013) HDL-apoA-I exchange: Rapid detection and association with atherosclerosis. PLoS One 8: E71541. 10.1371/journal.pone.0071541 [doi]; PONE-D-13-19304 [pii].
76. Stocker R, Keaney JF Jr. (2004) Role of oxidative modifications in atherosclerosis. Physiol Rev 84: 1381-1478. 10.1152/physrev.00047.2003 [doi]; 84/4/1381 [pii].
77. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, et al. (2000) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1. J Lipid Res 41: 1481-1494.
78. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, et al. (2000) Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3. J Lipid Res 41: 1495-1508.